The company is revolutionising molecular point-of-care diagnostics with a step change in speed, sensitivity, and cost. LEX is developing a 5-minute multiplex PCR test to quickly determine the presence of infectious diseases including SARS-CoV-2 (Covid-19), Influenza, Strep A, and RSV.
“I’m thrilled to join the talented team at LEX and to work toward launching our 5-minute multiplex PCR test. Our goal is to rapidly bring our innovative thermocycling technology to the healthcare market, improving patient care worldwide and opening the door to syndromic testing by bringing the necessary clinical insights to healthcare providers within minutes.” Ed Farrell, LEX Diagnostics CEO
LEX Diagnostics’ previous CEO and now Chair of the Board, Dr Andrew Baker-Campbell, said, “On behalf of the company, I welcome Ed to LEX Diagnostics. He brings an abundance of operational experience from his successful career spanning the diagnostics and medtech industry. We are confident Ed will drive the translation of our technology into a commercial product. I look forward to continuing my role as Chair of the Board, overseeing the strategy of this innovative and exciting molecular diagnostics company.”
Ed brings over 25 years of life science experience gained through senior industry roles with an emphasis on medical devices and diagnostics. Immediately prior to joining LEX Diagnostics Ed was COO of Klay Biotech. From 2013 to 2021 Ed served as President/COO of Quotient Ltd where he led the development and realisation of the MosaiQ platform from concept to commercialisation. He also played a significant role with Quotient’s IPO on Nasdaq. Prior to Quotient, Ed held senior positions in operations in the UK, USA, and Ireland with Siemens Healthcare Diagnostics. He holds a degree in Mechanical Engineering, and a Masters degree in Engineering Science, from University College Dublin.
Image: Ed Farrell, courtesy of TTP
